| 6.35 -0.21 (-3.2%) | 01-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.72 | 1-year : | 10.19 |
| Resists | First : | 7.46 | Second : | 8.72 |
| Pivot price | 6.1  |
|||
| Supports | First : | 5.95 | Second : | 5.02 |
| MAs | MA(5) : | 6.64 |
MA(20) : | 5.91 |
| MA(100) : | 6.77 |
MA(250) : | 5.84 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 59.4 |
D(3) : | 64.8 |
| RSI | RSI(14): 54.7 |
|||
| 52-week | High : | 9.34 | Low : | 1.91 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MASS ] has closed below upper band by 40.4%. Bollinger Bands are 24.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.63 - 6.67 | 6.67 - 6.71 |
| Low: | 6.13 - 6.17 | 6.17 - 6.22 |
| Close: | 6.27 - 6.34 | 6.34 - 6.42 |
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Sat, 24 Jan 2026
908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues - Sahm
Fri, 23 Jan 2026
Revenues Not Telling The Story For 908 Devices Inc. (NASDAQ:MASS) After Shares Rise 29% - 富途牛牛
Wed, 21 Jan 2026
908 Devices (MASS) Moves 19.2% Higher: Will This Strength Last? - Nasdaq
Tue, 20 Jan 2026
908 Devices Jumps On Improved Q4 And FY25 Preliminary Revenue - Nasdaq
Tue, 20 Jan 2026
908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025 - Business Wire
Tue, 20 Jan 2026
908 Devices reports 17% revenue growth, achieves positive EBITDA goal - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 36 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 8.3 (%) |
| Held by Institutions | 90.8 (%) |
| Shares Short | 3,310 (K) |
| Shares Short P.Month | 2,790 (K) |
| EPS | -2.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.76 |
| Profit Margin | -6.4 % |
| Operating Margin | -40.1 % |
| Return on Assets (ttm) | -16.5 % |
| Return on Equity (ttm) | -54.5 % |
| Qtrly Rev. Growth | -3.5 % |
| Gross Profit (p.s.) | 0.87 |
| Sales Per Share | 1.79 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -3.07 |
| PEG Ratio | 0 |
| Price to Book value | 1.68 |
| Price to Sales | 3.53 |
| Price to Cash Flow | -8.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|